Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. - Wikidata - awgldk - TriplyDB

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

http://www.wikidata.org/entity/Q36787777

about

Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma Molecularly targeted drugs for metastatic colorectal cancer Survival in glioblastoma: a review on the impact of treatment modalities.Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.N-(2-hydroxyphenyl)acetamide (NA-2) and Temozolomide synergistically induce apoptosis in human glioblastoma cell line U87.A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity Efficacy and safety of bevacizumab for the treatment of glioblastoma.Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.Update on anti-angiogenic treatment for malignant gliomas.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Glioblastoma multiforme: State of the art and future therapeutics.Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells Advances in Brain Tumor Surgery for Glioblastoma in Adults.

P2860

Q26767169-CB6C556C-4EE4-410A-9E5E-2A549CACB593 Q26828735-3FB419C3-E0FA-4A42-BB1C-5326CFAD393E Q30251810-BB5A0E22-FA87-40B3-BF83-3858BC309272 Q33627880-93F3828A-B80B-44E5-BA14-08AB3E84C3C8 Q35056313-6015C800-3492-49F6-9BF6-B0E5FB863879 Q35604265-FE6F7606-7E17-468A-94F4-2500B076FF0B Q36523864-C269B8AA-66D3-493E-A45A-963C623E2390 Q38129776-2209E319-B229-4DB9-8972-0CB4E037B865 Q38186658-59459A24-914A-4D57-8BB2-4A90F577EE52 Q38203283-0F0C55EA-F44B-495E-B663-14C3D6512910 Q38225874-7897176F-66E3-4207-BD98-962679432C8D Q38255001-54E5A123-66B3-40C3-B575-9EA0DB59F7B6 Q41525538-3AD0E9FE-89CF-4F4E-8E39-A0EB77117ED3 Q47904759-74414294-B335-4569-919A-B745D69DCBFA

P2860

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

http://www.wikidata.org/entity/Q36787777

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bevacizumab in high-grade glio ...... d future treatment challenges.

@en

type

label

Bevacizumab in high-grade glio ...... d future treatment challenges.

@en

prefLabel

Bevacizumab in high-grade glio ...... d future treatment challenges.

@en

P1433

Q36787777-57972C20-9854-4974-83FC-A1F6BDD38C5A

P1476

Q36787777-07BE66A8-AE5B-498A-AD53-ABBE595481FE

P2093

Q36787777-000FAAE3-FF4B-4CD8-A6F6-0F492B3D8FD3

Q36787777-189AD558-B74C-4BCB-B487-35B81DD6730E

Q36787777-3D5B52B7-4458-4E5F-B14E-71BDA578D751

P2860

Q36787777-00734B43-4E38-41C6-A5F5-251BF61F2EAA

Q36787777-00E4E2DB-5726-4175-BB6B-15A263C29D78

Q36787777-029FD515-D2AA-44D7-8E06-723FEAD3BC63

Q36787777-06908CB5-0CD9-40FD-97FC-CB46035A1B0A

Q36787777-09B76FFF-75D1-4A5F-8B6E-867BA593BA4E

Q36787777-0AC9F2D6-4E8F-4E2B-B736-A6CB5AA6C2B4

Q36787777-0B4DC42F-6171-43CA-8107-647B697379CC

Q36787777-0B8B53D0-0A2A-4C10-AD7F-B76C10BC76D1

Q36787777-0CD69745-F2C6-4202-BCA5-10E027E42334

Q36787777-0EC648DF-05FE-46D6-B15C-E627058B4E2B

P304

Q36787777-4E9219A0-6968-4F3F-9814-79429027E467

P31

Q36787777-EEB1D163-534E-4E33-B8D8-DA023CB52979

P356

Q36787777-6424A27B-A092-4F1B-9747-3468E4A1D5E7

P407

Q36787777-D70458AB-E965-4F6D-8394-909537869468

P478

Q36787777-9B921ECB-0281-4564-8160-6465E3078F46

P50

Q36787777-068D949E-5D76-432E-B557-A465782B50B3

P577

Q36787777-1AE9B275-6D26-4E84-B1D0-107939FBF35D

P5875

Q36787777-874387A7-7BC2-4EE5-AE5D-1174870E184C

P698

Q36787777-E5BD75EB-243E-42A3-885B-24BE30C7E0D5

P921

Q36787777-EE7862C7-DA73-4564-9D36-C69E26D049F4

P932

Q36787777-C1F26821-7D4C-4216-8E84-D3AB09FBC866

P356

P1433

OncoTargets and Therapy

P1476

Bevacizumab in high-grade glio ...... nd future treatment challenges

@en

P2093

Elizabeth J Hovey

http://www.w3.org/2001/XMLSchema#string

Manmeet S Ahluwalia

http://www.w3.org/2001/XMLSchema#string

Neda Hashemi-Sadraei

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

MGMT gene silencing and benefit from temozolomide in glioblastoma.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

A perivascular niche for brain tumor stem cells

P304

371-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S38628

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Gazanfar Rahmathulla

P577

2013-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236339692

http://www.w3.org/2001/XMLSchema#string

P698

23620671

http://www.w3.org/2001/XMLSchema#string

P921

P932

3633547

http://www.w3.org/2001/XMLSchema#string